Human-enabled
Machine-driven

Bespoke mini-proteins to help drug hunters deliver life-saving treatments.

Human-enabled

Machine-driven

Bespoke mini-proteins to help drug hunters deliver life-saving treatments.

Why Ordaōs

For each client, we create billions of proteins and evaluate their properties in silico to reliably and repeatedly deliver the de novo mini-proteins that drug hunters only dream of. We then prove our consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery.

We Create

We help birth novel therapies to reduce patient suffering and improve health.

Learn more

We Extend Life

We deliver safer and more effective life-saving treaments.

Learn more

We Innovate

Our flagship solution, miniPRO™ proteins, enable drug hunters to deliver safer and more effective treatments in a fraction of the time of traditional discovery methods.

Learn more

About miniPRO Proteins

Ordaōs miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to scale-up and manufacture. These proteins are 20x smaller than traditional monoclonal antibodies enabling them to more easily penetrate and effectively treat disease microenvironments.

Modular components
Stable structure
Configurable binding
Non-immunogenic

Symmetry in Motion

miniPRO™ proteins make up a group of 40~160 amino acid long proteins that independently fold into single domains. The proteins act as self-contained, configurable building blocks and are engineered for the therapeutic modality of choice.

We Accelerate Discovery

The Ordaōs Design Engine generates, appraises, and ranks billions of protein sequences, hundreds of thousands of protein structures and properties to create miniPRO™, our de novo class of mini-proteins.

Learn more

About Ordaōs Design Engine

The Ordaōs Design Engine is a generative perception engine that leverages reinforcement learning and proprietary data sets to translate human-targeted product criteria into machine-designed mini-proteins. The design engine produces proteins that are more therapeutically effective, less likely to cause adverse side effects, and are easier and less expensive to develop, test, and manufacture than traditional proteins.

Scalable, repeatable process
Quick turnaround, highly automated
Target and disease agnostic
Deep learning approach beyond rational combinatorial methods
Proprietary scoring method
Higher probability of success
Faster time to value

Benefits of Ordaōs System

Scalable
Repeatable
Highly Automated
Disease Agnostic
Perceptive System
Efficacy
Time to Value
IP Protected

Client Quote

"You accomplished in four-days what took us two-years to accomplish."

Dr. Philip Howe, Chair, Department of Chemistry,

Medical University of South Carolina

We Deliver

By maximizing drug candidate delivery speed, novelty, and probability of clinical success, we can provide the highest client confidence in every investigational new drug (IND) application.

What’s more, our clients see a return on their investment in weeks, rather than months or years.

See our latest news

Failure rate of drug discovery.

Drug development lifecycles.

Cost of each new drug released to market.

How Can Ordaōs Help You?

For Drug Hunters

We are a human-enabled, machine-driven drug design company that creates bespoke mini-proteins to help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods.

For Data Scientists

Our deep learning approach goes beyond rational combinatorial methods. We leverage a generative perception engine powered by reinforcement learning and proprietary data sets to translate human-targeted product criteria into machine-designed mini-proteins.

For Executives

By maximizing drug candidate delivery speed, novelty, and probability of clinical success, we can provide the highest client confidence in every investigational new drug (IND) application. What’s more, our clients see a return on their investment in weeks, rather than months or years.